Filgrastim BS F / Mochida
Filgrastim biosimilar developed by Fuji Pharma (with Mochida). Reference product Neupogen.
Brands by market: Filgrastim BS F and Mochida (Japan) · Commercial partner or holder: Fuji Pharma (with Mochida)
FDAnot listed
EMAnot listed
PMDANov 2012approved
HCnot listed
CDSCOnot listed
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
PMDA
Japan · Filgrastim BS F / Mochida
Pharmaceuticals and Medical Devices Agency and MHLWApprovedBrand
Filgrastim BS F / Mochida
Holder or applicant
Fuji Pharma; Mochida Pharmaceutical
Pathway
Biosimilar (MHLW approval on PMDA review)
Approved
Nov 2012
Indications as licensed
Neutropenia in chemotherapy, stem cell mobilisation, HIV, MDS, aplastic anaemia, congenital neutropenia
Presentations
75, 150 and 300 microgram syringes
Note
Filgrastim Biosimilar 1; reference product Gran; the Mochida-branded version is discontinued.
Source
S020
HC
Canada
Not listed by HC.
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- PMDANov 2012Approved by MHLW
Sources
S020PMDA, list of approved biosimilar products in Japan (as of July 2026) Primary (regulator)
Planning filgrastim biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.